Inventiva is a clinical‐stage biopharmaceutical company focused on the discovery and development of small‐molecule therapies for the treatment of non‐alcoholic steatohepatitis (NASH) and a range of rare and fibrotic diseases. Headquartered in Daix, France, with a subsidiary office in the United States, the company leverages its expertise in medicinal chemistry, preclinical research and clinical development to advance novel compounds from the laboratory to human studies.
The company’s lead asset, lanifibranor, is an investigational pan‐PPAR agonist in Phase II/III clinical trials for the treatment of NASH, a chronic liver disease with few approved therapies. In addition to its liver‐focused program, Inventiva is advancing a diversified pipeline that includes small‐molecule candidates for fibrotic disorders, lysosomal storage diseases such as mucopolysaccharidosis type VI, and Duchenne muscular dystrophy. These programs reflect Inventiva’s strategy to leverage shared mechanistic insights across metabolic, fibrotic and genetic conditions.
Founded in 2012 by a team of drug discovery specialists, Inventiva has established collaborative partnerships with leading academic institutions and contract research organizations in Europe and North America. The company operates in full compliance with regulatory requirements set by the U.S. Food and Drug Administration and the European Medicines Agency, and it has demonstrated an ability to design and execute complex clinical studies in multiple geographic regions.
Inventiva’s executive leadership brings together seasoned professionals with decades of experience in biotechnology and pharmaceutical development. Under the guidance of CEO Dr. Hervé Seligmann, the team combines scientific rigor with strategic business acumen to advance its pipeline. With a global footprint spanning Europe and the United States, Inventiva aims to address significant unmet medical needs and deliver innovative therapies to patients worldwide.
AI Generated. May Contain Errors.
